SCHEMBL26601719

SCHEMBL26601719

Cc1nc(Cl)cc(OCc2ccccc2)c1N(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ STAT3 P40763 2/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ MAPK1 P28482 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ MCL1 Q07820 1/20 0.41
▸ ATP4A P20648 2/20 0.40
▸ ATP4B P51164 2/20 0.40
▸ BRD4 O60885 3/20 0.40
▸ CCR5 P51681 1/20 0.40
▸ GCK P35557 1/20 0.40
▸ RHEB Q15382 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ TLR9 Q9NR96 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601837 0.83 HTT (0.44) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL4781292 0.82 HTT (0.54) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL26601820 0.82 HTT (0.54) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL26608482 0.81 HTT (0.46) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL30624527 0.80 ALDH1A1 (0.44) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL26601633 0.80 ALDH1A1 (0.44) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL26601702 0.80 HTT (0.51) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL26601848 0.80 HTT (0.51) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL26601651 0.80 HTT (0.51) HTTSMN1; SMN2STAT3L3MBTL1MAPT
SCHEMBL31747854 0.79 CCR5 (0.50) HTTSMN1; SMN2STAT3L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 — — US disclosed
EP-4511117-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 HTT 1485/4885SMN1; SMN2 760/4885STAT3 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback